4//SEC Filing
Laliberte Kevin 4
Accession 0001209191-19-044032
CIK 0001685071other
Filed
Jul 31, 8:00 PM ET
Accepted
Aug 1, 4:31 PM ET
Size
7.9 KB
Accession
0001209191-19-044032
Insider Transaction Report
Form 4
Laliberte Kevin
Sr. VP, Product Development
Transactions
- Sale
Common Stock
2019-07-31$15.97/sh−1,389$22,182→ 11,557 total - Award
Employee Stock Option (right to buy)
2019-07-30+10,000→ 10,000 totalExercise: $16.08Exp: 2029-07-30→ Common Stock (10,000 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.60 to $16.09 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
- [F3]One-fourth (1/4th) of the shares vest July 30, 2020, and the balance of the shares vest in a series of thirty-six (36) successive equal monthly installments thereafter, subject to the Reporting Persons continuous service as of each such date.
Documents
Issuer
Dova Pharmaceuticals Inc.
CIK 0001685071
Entity typeother
Related Parties
1- filerCIK 0001709417
Filing Metadata
- Form type
- 4
- Filed
- Jul 31, 8:00 PM ET
- Accepted
- Aug 1, 4:31 PM ET
- Size
- 7.9 KB